Yeni Şafak English

No proof Trump touted drug is effective against coronavirus, EU says

News Service
14:1731/03/2020, Tuesday
U: 31/03/2020, Tuesday
REUTERS
U.S. President Donald Trump addresses the daily coronavirus response briefing in the Rose Garden at the White House in Washington, U.S., March 30, 2020. REUTERS/Tom Brenner
U.S. President Donald Trump addresses the daily coronavirus response briefing in the Rose Garden at the White House in Washington, U.S., March 30, 2020. REUTERS/Tom Brenner

The European Commission said on Tuesday there was no evidence that a drug touted by U.S. President Donald Trump as a potential miracle cure against COVID-19 was effective against the disease caused by the new coronavirus.

Trump had said that hydroxychloroquine, an anti-malaria drug, could be among "the biggest game changers in the history of medicine" for its potential effects against COVID-19.

"The efficacy of hydroxychloroquine in the treatment of COVID-19 patients has to date not been proved," a spokesman for the European Commission said on Tuesday, relaying an internal opinion from the European Medicine Agency.

The spokesman said there was also no evidence either of the positive effects of chloroquine, another malaria drug, which is also being tested for its possible use against COVID-19.

The U.S. Health and Human Services on Thursday listed hydroxychloroquine as a protected medical resource after Trump signed an executive order to prevent its hoarding and price gouging.

Hungary, a European Union member, last week the commercial export of hydroxychloroquine.

"As Hungary is one of the world's largest exporters of this ingredient, the protection and medical supply of the Hungarian population is now a priority," the government said.

#Donald Trump
Comments

Hello, the comments you share on our site are a valuable resource for other users. Please respect other users and different opinions. Do not use rude, offensive, derogatory, or discriminatory language.

No comments yet

The floor is all yours.

Click here to receive the most important news of the day by email. Subscribe here.

By subscribing, you agree to receive electronic communications from Albayrak Media Group websites and accept the Terms of Use and Privacy Policy.